| Name | Title | Contact Details |
|---|
Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients. These include modifiers of Sweet and Salt flavors as well as Savory Flavors, Bitter Blockers, and Cooling Agents. The Company is also engaged in an effort to discover and develop natural high-potency sweeteners. Under its direct sales program, Senomyx is beginning to sell certain of its Complimyx brand flavor ingredients, Sweetmyx, Savorymyx, and Bittermyx, to flavor companies for re-sale to their food and beverage company customers. In addition, Senomyx has collaborative agreements with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx's flavor ingredients.
BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. Today we have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. Our Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. Our mission is to provide imaginative new ways to treat disease; making a real difference for patients, and a valuable contribution to healthcare. As medicine moves from major surgery to minor procedure, no company endeavours to do more to help doctors in their quest to see more, reach further and treat smarter. We understand their needs and equip them with tools and techniques that would have seemed like science fiction only a generation ago. We invest in clinical evidence that helps demonstrate the value of our treatments to patients, doctors, and healthcare systems. With relentless curiosity we`ll work with clinicians to find elegant new ways to extend our power over disease and transform patient care. There are no limits to where our ideas will take us.
Wellness programs are out. Wellbeing strategies are in. To thrive today, organizations must be trustworthy while nurturing a culture where people do their best work. There’s no shortcut to true potential, but CHC has a proven roadmap to reduce benchmar...
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
Adia Information Management Corp. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.